Cargando…

Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab

The mechanisms that contribute to the maintenance of serological memory are still unclear. Rotavirus (RV) memory B cells (mBc) are enriched in IgM(+) and CD27(-) subpopulations, which are associated with autoimmune diseases pathogenesis. In patients with autoimmune diseases treated with Rituximab (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera, Daniel, Rojas, Olga L., Duarte-Rey, Carolina, Mantilla, Rubén D., Ángel, Juana, Franco, Manuel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018270/
https://www.ncbi.nlm.nih.gov/pubmed/24819618
http://dx.doi.org/10.1371/journal.pone.0097087
_version_ 1782480042588110848
author Herrera, Daniel
Rojas, Olga L.
Duarte-Rey, Carolina
Mantilla, Rubén D.
Ángel, Juana
Franco, Manuel A.
author_facet Herrera, Daniel
Rojas, Olga L.
Duarte-Rey, Carolina
Mantilla, Rubén D.
Ángel, Juana
Franco, Manuel A.
author_sort Herrera, Daniel
collection PubMed
description The mechanisms that contribute to the maintenance of serological memory are still unclear. Rotavirus (RV) memory B cells (mBc) are enriched in IgM(+) and CD27(-) subpopulations, which are associated with autoimmune diseases pathogenesis. In patients with autoimmune diseases treated with Rituximab (RTX), some autoantibodies (auto-Abs) decrease after treatment, but other auto-Abs and pathogen-specific IgG Abs remain unchanged. Thus, maintenance of autoimmune and pathogen-specific serological memory may depend on the type of antigen and/or Ab isotype evaluated. Antigen-specific mBc and antigen-specific Abs of different isotypes have not been simultaneously assessed in patients after RTX treatment. To study the relationship between mBc subpopulations and serological memory we characterized total, RV- and tetanus toxoid (TT)-specific mBc by flow cytometry in patients with autoimmune diseases before and after treatment with RTX. We also measured total, RV- and TT-Abs, and some auto-Abs by kinetic nephelometry, ELISA, and EliA tests, respectively. Minor differences were observed between the relative frequencies of RV-mBc in healthy controls and patients with autoimmune disease. After RTX treatment, naïve Bc and total, RV- and TT-specific mBc [IgM(+), switched (IgA(+)/IgG(+)), IgM(+) only, IgD(+) only, and CD27(-) (IgA(+)/IgG(+)/IgM(+))] were significantly diminished. An important decrease in total plasma IgM and minor decreases in total IgG and IgA levels were also observed. IgM rheumatoid factor, IgG anti-CCP, and IgG anti-dsDNA were significantly diminished. In contrast, RV-IgA, RV-IgG and RV-IgG(1), and TT-IgG titers remained stable. In conclusion, in patients with autoimmunity, serological memory against RV and TT seem to be maintained by long-lived plasma cells, unaffected by RTX, and an important proportion of total IgM and serological memory against some auto-antigens seem to be maintained by short-lived plasma cells, dependent on mBc precursors depleted by RTX.
format Online
Article
Text
id pubmed-4018270
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40182702014-05-16 Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab Herrera, Daniel Rojas, Olga L. Duarte-Rey, Carolina Mantilla, Rubén D. Ángel, Juana Franco, Manuel A. PLoS One Research Article The mechanisms that contribute to the maintenance of serological memory are still unclear. Rotavirus (RV) memory B cells (mBc) are enriched in IgM(+) and CD27(-) subpopulations, which are associated with autoimmune diseases pathogenesis. In patients with autoimmune diseases treated with Rituximab (RTX), some autoantibodies (auto-Abs) decrease after treatment, but other auto-Abs and pathogen-specific IgG Abs remain unchanged. Thus, maintenance of autoimmune and pathogen-specific serological memory may depend on the type of antigen and/or Ab isotype evaluated. Antigen-specific mBc and antigen-specific Abs of different isotypes have not been simultaneously assessed in patients after RTX treatment. To study the relationship between mBc subpopulations and serological memory we characterized total, RV- and tetanus toxoid (TT)-specific mBc by flow cytometry in patients with autoimmune diseases before and after treatment with RTX. We also measured total, RV- and TT-Abs, and some auto-Abs by kinetic nephelometry, ELISA, and EliA tests, respectively. Minor differences were observed between the relative frequencies of RV-mBc in healthy controls and patients with autoimmune disease. After RTX treatment, naïve Bc and total, RV- and TT-specific mBc [IgM(+), switched (IgA(+)/IgG(+)), IgM(+) only, IgD(+) only, and CD27(-) (IgA(+)/IgG(+)/IgM(+))] were significantly diminished. An important decrease in total plasma IgM and minor decreases in total IgG and IgA levels were also observed. IgM rheumatoid factor, IgG anti-CCP, and IgG anti-dsDNA were significantly diminished. In contrast, RV-IgA, RV-IgG and RV-IgG(1), and TT-IgG titers remained stable. In conclusion, in patients with autoimmunity, serological memory against RV and TT seem to be maintained by long-lived plasma cells, unaffected by RTX, and an important proportion of total IgM and serological memory against some auto-antigens seem to be maintained by short-lived plasma cells, dependent on mBc precursors depleted by RTX. Public Library of Science 2014-05-12 /pmc/articles/PMC4018270/ /pubmed/24819618 http://dx.doi.org/10.1371/journal.pone.0097087 Text en © 2014 Herrera et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Herrera, Daniel
Rojas, Olga L.
Duarte-Rey, Carolina
Mantilla, Rubén D.
Ángel, Juana
Franco, Manuel A.
Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab
title Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab
title_full Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab
title_fullStr Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab
title_full_unstemmed Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab
title_short Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab
title_sort simultaneous assessment of rotavirus-specific memory b cells and serological memory after b cell depletion therapy with rituximab
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018270/
https://www.ncbi.nlm.nih.gov/pubmed/24819618
http://dx.doi.org/10.1371/journal.pone.0097087
work_keys_str_mv AT herreradaniel simultaneousassessmentofrotavirusspecificmemorybcellsandserologicalmemoryafterbcelldepletiontherapywithrituximab
AT rojasolgal simultaneousassessmentofrotavirusspecificmemorybcellsandserologicalmemoryafterbcelldepletiontherapywithrituximab
AT duartereycarolina simultaneousassessmentofrotavirusspecificmemorybcellsandserologicalmemoryafterbcelldepletiontherapywithrituximab
AT mantillarubend simultaneousassessmentofrotavirusspecificmemorybcellsandserologicalmemoryafterbcelldepletiontherapywithrituximab
AT angeljuana simultaneousassessmentofrotavirusspecificmemorybcellsandserologicalmemoryafterbcelldepletiontherapywithrituximab
AT francomanuela simultaneousassessmentofrotavirusspecificmemorybcellsandserologicalmemoryafterbcelldepletiontherapywithrituximab